Sanofi
ORI Capital exits investment in Kymab to Sanofi in a $1.1B deal, announces upcoming $400M ORI Fund II
Hong Kong-based healthcare fund management firm ORI Capital has decided to exit Kymab, a British biopharmaceutical company that specializes in vaccines and novel drug solutions.…
Perspectives: Who Pays for HealthTech?
Note: This session was the second in the three-part series "Asia’s Most Wanted—Digital Health" organised by BlueChilli HealthTech and TechNode Global. The global…
